ClinicalTrials.gg
SuspendedNCT04996030Updated Jan 23, 2024

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

A Phase 1 interventional study of SY-2101 and Arsenic Trioxide in Acute Promyelocytic Leukemia, sponsored by Syros Pharmaceuticals. Suspended at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Syros Pharmaceuticals · Phase 1, Interventional, and Treatment

Why this study was suspended
Prioritization

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing Arsenic Trioxide in Leukemia, Promyelocytic, Acute — 3 open to participants now, 5 under way, 2 of them phase 3. Arsenic Trioxide · Leukemia, Promyelocytic, Acute.

Enrollment
14th of 19
16 · median 60
Started
2021
the only one that year
Phase 1
2 of 20
none open now
Registered
16th of 20
by date

Among the 20 studies testing Arsenic Trioxide in Leukemia, Promyelocytic, Acute, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2021, is one of 2 in phase 1, and was the 16th registered.

Leukemia, Promyelocytic, Acute

134 studies on the registry are indexed under Leukemia, Promyelocytic, Acute; 16 are open to participants now.

Browse Leukemia, Promyelocytic, Acute studies →

Open to participants now

3 of the 20 studies testing Arsenic Trioxide in Leukemia, Promyelocytic, Acute are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Arsenic Trioxide

Arsenic Trioxide: first FDA approval 2000 (TRISENOX), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Leukemia, Promyelocytic, Acute studies recruiting now, 7 (58%) set no upper age limit and 5 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing Arsenic Trioxide in Leukemia, Promyelocytic, Acute, or all of them as a file.
02

Study summary

SY-2101 is being studied as a treatment for participants with a type of leukemia called acute promyelocytic leukemia (APL). SY-2101 is an oral formulation of a drug called arsenic trioxide (ATO). ATO is already used to treat APL in a formulation that is given as an intravenous (IV) infusion (through a needle in the arm). SY-2101 is a formulation of ATO that is taken orally (by mouth).

This trial will include participants with APL in remission, who are receiving standard of care (SOC) treatment with all-trans-retinoic acid (ATRA) and IV ATO, during the consolidation phase of chemotherapy or within the past 6 months. The participants in this trial will receive continued treatment with ATO and ATRA to help keep their cancer from coming back. There will be some weeks when participants receive IV ATO and others when they receive SY-2101 (ATO taken orally). Participants with high-risk APL may be eligible for part 1 or 4 of the study for the 6 months following completion of their standard of care ATRA and ATO treatment.

Read the detailed description

This study includes 4 parts. In the first part, enrolled participants will receive a single dose of IV ATO, followed a week later by a single dose of SY-2101, SY-2101 will be administered to participants in either a fed or a fasted condition. A week after that, participants will receive a second, a single dose of SY-2101, with some participants taking this dose in a fed state and other participants taking this dose in a fasted condition. After each of these doses, blood draws and safety assessments will be performed. In the second part, enrolled participants will receive IV ATO according to the standard of care, with collection of blood and safety assessments. In the third part, enrolled participants who are documented to be in molecular remission will receive SY-2101 in place of IV ATO during the 4th cycle of consolidation, with the collection of blood and safety assessments throughout the cycle. In the fourth part, enrolled participants will receive two single-dose treatments of SY-2101 approximately one week apart.

03

Conditions studied

  • Acute Promyelocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must have a diagnosis of APL characterized by the presence of the t(15;17) translocation or PML/RARA gene expression via reverse transcription polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), or cytogenetics. Participants with low-risk APL may be eligible for all parts of this study; participants with high-risk APL are only eligible for the single-dose modules if they have completed a treatment regimen that included ATO within 6 months prior to the Screening Visit.
  • Participants must have received ATO plus ATRA induction therapy and must have received or be eligible and planning to receive consolidation therapy with ATO plus ATRA in alignment with National Comprehensive Cancer Network (NCCN) guidelines for low-risk APL prior to their enrollment in the study; or participants must have completed a treatment regimen that included ATO within 6 months prior to the Screening Visit.
  • Participants must be able to tolerate full dose ATO per NCCN guidelines.
  • Participants must be in morphological complete remission (CR) at the end of induction.
  • Participants must have a serum or high-sensitivity urine pregnancy test (for females of ) that is negative at the Screening Visit and immediately prior to initiation of study treatment (first dose of study drug).

Key Exclusion Criteria:

  • Participants who have demonstrated relapse and therefore are not eligible for further consolidation.
  • Participants currently receiving treatment for a non-APL (not including basal cell carcinoma, non-melanoma skin cancer, cervical carcinoma in situ, or localized prostate cancer treated with hormone therapy). Participants with history of other cancers should be free of disease for at least 2 years prior to the Screening Visit.
  • Participants with an active, life-threatening, or clinically-significant uncontrolled systemic infection requiring hospitalization.
  • participants with increased risk of opportunistic infections, including known (HIV)-positive participants with cluster of differentiation 4 (CD4) counts ≤350 cells/millimeters (mm\^3) or history of opportunistic infection in the last 12 months.
  • Participants with a known active or chronic or active virus (HCV) infection. Participants with a history of HCV infection who have completed curative therapy for HCV at least 12 weeks before the Screening Visit and have a documented undetectable viral load at the Screening Visit are eligible for enrollment.
  • Participants who have not adequately recovered from a major surgery within 4 weeks of starting study drug administration.
  • Participants who received any other agents within 4 weeks of the Screening Visit or \<5 half-lives since completion of previous investigational therapy have elapsed, whichever is shorter.
  • Participants who have a to arsenic.
  • Participants who have experienced the following Grade ≥3 non-hematologic toxicities associated with ATO administration: , hepatotoxicity, neurotoxicity, cardiac function abnormalities. Participants who experienced other severe and life-threatening clinically-significant ATO-related AEs that are considered, in the judgement of the investigator, to increase participant risk with continued ATO treatment are also excluded.

Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Single-Dose PK Module: Sequence 1

    Participants will receive IV ATO in a fasted state on Day 1, SY-2101 in a fed state on Day 8, and SY-210 in a fasted state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle.

    Drug: SY-2101 · Drug: Arsenic Trioxide

  • Experimental
    Single-Dose PK Module: Sequence 2

    Participants will receive IV ATO in a fasted state on Day 1, SY-2101 in a fasted state on Day 8, and SY-2101 in a fed state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle.

    Drug: SY-2101 · Drug: Arsenic Trioxide

  • Experimental
    Single-Dose PK Comparability Module

    Participants will receive two single-dose treatments of SY-2101, with separated from one another by approximately 1 week and separated from any preceding IV ATO dose by at least 72 hours.

    Drug: SY-2101

  • Experimental
    Multiple-Dose IV Module

    Participants will receive IV ATO, once daily (QD), 5 days/week for 28 days as a part of at least one cycle (Weeks 1 through 4) of SOC treatment consolidation.

    Drug: Arsenic Trioxide

  • Experimental
    Multiple-Dose Oral Module

    Participants will receive SY-2101, QD, 5 days/week for 28 days as a part of one cycle (Cycle 4; Weeks 1 through 4) of SOC treatment consolidation.

    Drug: SY-2101

Interventions

  • SY-2101 will be administered per dose and schedule specified in arm description.

    Also known as: Oral ATO, Oral Arsenic Trioxide

  • IV ATO will be administered per dose and schedule specified in arm description.

    Also known as: IV ATO, Trisenox®, IV Arsenic Trioxide

06

What researchers measure

Primary outcomes

  1. Single-Dose Module: Maximum Observed Plasma Concentration (Cmax) of SY-2101

    Time frame: Predose and up to 168 hours postdose

  2. Single-Dose Module: Area Under the Curve (AUC) of SY-2101

    Time frame: Predose and up to 168 hours postdose

  3. Multiple-Dose Module: Cmax of SY-2101

    Time frame: Predose and up to 6 hours postdose on Day 5 and up to 4 hours postdose on Day 26

  4. Multiple-Dose Module: AUC of SY-2101

    Time frame: Predose and up to 6 hours postdose on Day 5 and up to 4 hours postdose on Day 26

Secondary outcomes

  1. Single-Dose Module: Cmax of ATO

    Time frame: Predose and up to 168 hours postdose

  2. Single-Dose Module: AUC of ATO

    Time frame: Predose and up to 168 hours postdose

  3. Multiple-Dose Module: Cmax of ATO

    Time frame: Predose and up to 6 hours postdose on Day 5 and up to 4 hours postdose on Day 26

  4. Multiple-Dose Module: AUC of ATO

    Time frame: Predose and up to 6 hours postdose on Day 5 and up to 4 hours postdose on Day 26

  5. Number of Participants With Adverse Events

    Time frame: up to Day 23 for single-dose module and up to Day 56 for multiple-dose module

07

Study locations

8 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60208, United States
  • John Hopkins University
    Baltimore, Maryland 21287, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jan 2024, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2021
First posted
Aug 9, 2021
StartActual
Sep 17, 2021
Primary completionActual
Jan 3, 2024
CompletionEst.
Apr 2024
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04996030
Lead sponsor
Syros Pharmaceuticals
Responsible party
Sponsor
First posted
Aug 9, 2021
Start date
Sep 17, 2021
Primary completion
Jan 3, 2024
Completion
Apr 2024 (estimated)
Last update
Jan 23, 2024

Study contacts

Medical Director, MD
study director · Syros Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arsenic Trioxide

Start the discussion